Reading AZTA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AZTA free→
AZTA
Azenta, Inc.NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-12
Watch· this month
$22.59+0.58%
Close 2026-06-12 · 1-day change
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
The bottom line
Recent financial performance is weak, and earnings quality cannot be assessed as the company was unprofitable over the past year. Risk is elevated, and the sector backdrop is a headwind, with performance compared to sector peers being below typical. Peer multiples imply a price about 5% below where it trades (it looks expensive on this basis); the read is fair, but weakening. This assessment hinges on whether AZTA cuts guidance on the next call, which could negatively impact estimates. This read is provisional.
as of 2026-06-12
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Medical Instruments & Supplies
- Market cap
- $1.01B
- Employees
- 3,000
- IPO date
- 1996-05-09
- Next earnings
- 2026-08-04
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 6 valuation methods, at three horizons. Current price $22.59. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryfull
$21.48consensus
Range $14.42 – $31.63
vs price: +5% above
Method agreement — · 6 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearinexpensive
$54.84consensus
Range $45.70 – $59.97
vs price: -59% below
Method agreement — · 4 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Durable premiummedium confidence
At $23 the market pays 50× p/e — above the 27× p/e peer median but in line with its own 57× history. That premium reflects a durable franchise our peer-anchored $22 fair value understates; treat the 'expensive vs peers' read with medium confidence. Not investment advice.
Multiple (P/E)
50.2x
peer 27.0x · own history 57.1x
Premium
1.9x peer
0.9x its own history
Growth the price needs
5%
our forecast -7%
Our fair value
$21.56
range $14.46 – $31.63
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
fullfair — but weakening12-month view
What's priced inStretched
The market is pricing in roughly 5% near-term growth, ahead of our forecast of about -7%. This describes what's priced in, not a forecast of the move.
Low fragilityrisk posture, not a price call
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Historical context
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
weakOperating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
0th pctl · Health Care
Earnings quality
loss makingOver the trailing year it converted -0.36x of net income into operating cash flow.
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
Management & capital allocation
Not enough signal yet.
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Strongly bearishEPS revised -56.9% / 30d, n=5for period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $0.23 → $0.10 (-56.9% / 30d). 0 raised, 4 cut, 5 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d. 50% of analysts rate Buy.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Secular epoch: Mature by revenue growth · theme AI-drug-discovery.Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: neutral
- Capital allocation
- neutral
- Earnings discipline
- neutral
- Margin discipline
- weak
- Balance sheet
- neutral
- Post-call reaction
- strong
A guidance track record builds as the company issues and delivers on guidance.
as of 2026-06-12
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$238.
How much price usually moves either way.
On a bad day, this stock has moved -$512.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,094.
Deepest peak-to-trough drop in the last year.
elevatedas of 2026-06-12
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- label change · signal_labelmoderate change
Signal changed from 'mixed' to 'cautious'.
- label change · valuation_labelsmall change
Valuation label changed from 'fair' to 'full'.
As of June 12, 2026, the signal label changed to "cautious," indicating a shift in outlook. The valuation label also changed to "full," suggesting a different assessment of the stock's value. These changes reflect adjustments in market perception and valuation context.
as of 2026-06-12
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- DownsideHigh confidenceMonthsactive 14d
Watch for Q2 operating income worsening beyond -$165.8M
Why it matters: A bigger loss in operating income shows management is having a hard time making more money. This might hurt investor confidence.
What confirms / what disproves
Confirms:Operating income reported worse than -$165.8M in Q2.
Disproves:Operating income improves or stays better than -$165.8M.
Management priorities
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for AZTA yet.
This sector is also watching
- Watch for Health Care revenue growth dropping below 8% YoY
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like ISRG, MDLN, and BDX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting AZTA and other Healthcare names. Worth watching these names for early signals.
- If AZTA raises forward guidance on the next earnings call (currently NEW as of 2026-05-05), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for AZTA and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If AZTA cuts guidance on the next call (currently NEW as of 2026-05-05), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like ISRG, MDLN, and BDX start missing or guiding lower, the Healthcare tailwind helping AZTA and other Healthcare names could fade. Watch these names for early warning.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-051mo agoItem 2.02
and Exhibit 99.1 to this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-Looking Statements. Except for historical information con…
Earnings preannouncement—
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+10 vs last weeklatest as of 2026-06-13
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.